curasan AG: One Million Units of Cerasorb® Produced -- MEDICA - World Forum for Medicine


curasan AG

curasan AG: One Million Units of Cerasorb® Produced

Mehler and Roessler with the 1,000,000th unit of_Cerasorb M.

Kleinostheim, Germany, 28th April 2010 – The employees of curasan AG awaited the recently produced batch of Cerasorb® M with particular excitement – because amongst this batch was the one millionth bottle ready for sale. Depending on requirements, the bottles contain between 0.5 and 30 grams of the synthetic bone substitute material. The batch was part of a production order placed by Riemser Arzneimittel AG, which has been selling Cerasorb® in the dental market since mid 2008.

Dr. Fabian Peters, Technical Director at curasan AG, handed over both the 1,000,000th and the 1,000,001st unit, to Hans Dieter Rössler, CEO of curasan AG and Dr. Michael Mehler, CEO of Riemser Arzneimittel AG.

“This represents to us yet another milestone in this product’s twelve-year success story. We estimate that more than 800,000 patients worldwide have been treated with the one million units sold to date”, explained Hans Dieter Rössler.

Dr. Michael Mehler added: “We at Riemser Arzneimittel AG are pleased to have contributed towards the reaching of this magical number with our sales activities. Our customers in the dentistry market appreciate the value of a safe and proven product such as Cerasorb®.”

Cerasorb® is the global reference standard in its substance class and has been expanded over the last few years to an umbrella brand for diverse product variants. The product is not only employed in the field of dentistry, but also in a broad spectrum of indications in orthopaedics and traumatology. curasan’s research & development experts are working on a range of new product developments which are to be launched onto the market over the next couple of years.

Background information about curasan AG:
Exchange listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms in the field of regenerative medicine especially in bone and tissue regeneration. In addition to the synthetic Cerasorb® bone substitution and regeneration material, the company has developed a future-oriented product pipeline. The goal during the next few years is to have further medical products ready for market rollout via well-positioned contractual partners in various market segments.

Picture: Mehler and Roessler with the 1,000,000th unit of_Cerasorb M